Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Patrick K. Reville"'
Autor:
Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Sherry Pierce, Carlos E. Bueso-Ramos, Hussein A. Abbas, Marina Konopleva, Tapan M. Kadia, Maro Ohanian, Patrick K. Reville, Hagop M. Kantarjian, Caitlin R. Rausch, Alexis Geppner, Koji Sasaki, Naveen Pemmaraju, Gautam Borthakur, Naval Daver, Courtney D. DiNardo
Publikováno v:
Leuk Lymphoma
Myeloid sarcoma in the setting of concomitant medullary AML is relatively well described, while much less is known about patients presenting with myeloid sarcoma with < 20% bone marrow blasts. We conducted a retrospective analysis of 56 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac41a6e525de0ac4bf75b16ec6bb490
https://europepmc.org/articles/PMC8939853/
https://europepmc.org/articles/PMC8939853/
Autor:
Rebecca S. S. Tidwell, Sa A. Wang, Naval Daver, Musa Yilmaz, Yesid Alvarado, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Guillermo Garcia-Manero, Nitin Jain, Nicholas J. Short, Steven M. Kornblau, Gautam Borthakur, Rabiul Islam, Hagop M. Kantarjian, Patrick K. Reville, Marina Konopleva
Publikováno v:
Lancet Haematol
Summary Background Addition of the BCL2 inhibitor venetoclax to lower intensity therapy has been shown to improve overall survival in older (aged 75 years or older) and unfit patients with newly diagnosed acute myeloid leukaemia. The aim of this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d51d3854846c1936e9e71a1b7fa758e
https://europepmc.org/articles/PMC8884174/
https://europepmc.org/articles/PMC8884174/
Autor:
Courtney D. DiNardo, Maro Ohanian, Zeev Estrov, Patrick K. Reville, Prithviraj Bose, Sa A. Wang, Michael Andreeff, Farhad Ravandi, Musa Yilmaz, Naval Daver, Lucia Masarova, Hagop M. Kantarjian, Tapan M. Kadia, Yesid Alvarado, Guillermo Garcia-Manero, Nicholas J. Short, Rebecca S. S. Tidwell, Guillermo Montalban-Bravo, Nitin Jain, Gautam Borthakur, Elias Jabbour, Steven M. Kornblau, Marina Konopleva
Publikováno v:
Blood. 136:7-9
Background Addition of the BCL2 inhibitor venetoclax to lower intensity therapy improved survival (OS) for older and unfit patients with newly diagnosed AML. We have previously reported the safety and efficacy of the nucleoside analogue cladribine co
Autor:
Ruiping Wang, Zoe Alaniz, Praveen Barrodia, Courtney D. DiNardo, Guillermo Garcia-Manero, Latasha Little, Michael R. Green, Koichi Takahashi, Gheath Alatrash, Wei Wang, Dapeng Hao, P. Andrew Futreal, Jairo Matthews, Jin S. Im, Farhad Ravandi, Steven M. Kornblau, Kunal Rai, Feng Wang, Maomao Ding, Linghua Wang, Jing Ning, Jianhua Zhang, Gautam Borthakur, Patrick K. Reville, James P. Allison, Naval Daver, Padmanee Sharma, Hussein A. Abbas, Marina Konopleva, Katarzyna Tomczak, Tapan M. Kadia, Sreyashi Basu
Publikováno v:
Blood. 136:29-31
Background The success of allogenic stem cell transplantation in curing AML suggests that the immune system can be harnessed to eradicate AML. In a phase 2 trial (NCT02397720) in relapsed/refractory (R/R) AML patients, we demonstrated that the azacit
Autor:
Lianchun Xiao, Sanam Loghavi, Marina Konopleva, Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, Gheath Alatrash, Elias Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Yesid Alvarado, Caitlin R. Rausch, Hagop M. Kantarjian, Maro Ohanian, Jorge E. Cortes, Farhad Ravandi
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Autor:
Patrick K. Reville, Tapan M. Kadia
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Frontiers in Oncology
Frontiers in Oncology
Recent advances in therapeutics coupled with steady improvements in supportive care for patients with acute myeloid leukemia (AML) have led to improved outcomes. Despite these advances, even in patients that achieve a complete remission with initial
Autor:
Hussein A. Abbas, Patrick K. Reville, Xianli Jiang, Hui Yang, Alexandre Reuben, Jin Seon Im, Latasha Little, Jefferson C. Sinson, Ken Chen, Andrew Futreal, Guillermo Garcia-Manero
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Aberrant T-cell function is implicated in the pathogenesis of myelodysplastic syndrome (MDS). Monitoring the T-cell receptor (TCR) repertoire can provide insights into T-cell adaptive immunity. Previous studies found skewed TCR repertoires in MDS com
Autor:
Kunal Rai, Jairo Matthews, Linghua Wang, Naval Daver, Zoe Alaniz, Feng Wang, Katarzyna Tomczak, Guillermo Garcia-Manero, Jianhua Zhang, Jin Seon Im, Padmanee Sharma, Gheath Alatrash, Maomao Ding, Jing Ning, Praveen Barrodia, Dapeng Hao, Latasha Little, Koichi Takahashi, Ruiping Wang, Wei Wang, Sreyashi Basu, Patrick K. Reville, Hussein A. Abbas, James P. Allison, Marina Konopleva, Steven M. Kornblau, Michael R. Green, Andrew Futreal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Allogeneic stem cell transplantation can cure relapsed/refractor (R/R) AML via grafted T cells versus leukemia effect, but not a viable option to many patients. By combining azacitidine with nivolumab, we harnessed T cell activity and demo
Autor:
Ruiping Wang, Praveen Barrodia, Jairo T. Mathews, Hussein A. Abbas, Gheath Alatrash, Marina Konopleva, Steven M. Kornblau, Dapeng Hao, Kunal Rai, Patrick K. Reville, Andrew Futreal, Sreyashi Basu, Naval Daver, Latasha Little, Linghua Wang, Katarzyna Tomczak, Koichi Takahashi, Padmanee Sharma, Wei Wang, Maomao Ding, Jianhua Zhang, Guillermo Garcia-Manero, James P. Allison, Jing Ning, Feng Wang, Jin Seon Im, Zoe Alaniz, Michael R. Green
Acute myeloid leukemia (AML) and effector cells of immune checkpoint blockade (ICB) therapy co-reside in a complex bone marrow (BM) milieu. The interplay of tumor intrinsic and microenvironment (TME) mechanisms that influences the response to ICB-bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57b3a205161dd7a512dcb8c9562a23eb
https://doi.org/10.1101/2020.09.03.278309
https://doi.org/10.1101/2020.09.03.278309
Autor:
Elias Jabbour, Koichi Takahashi, Kapil N. Bhalla, Guillermo Garcia-Manero, Rashmi Malla, Naval Daver, Caitlin R. Rausch, Naveen Pemmaraju, Nitin Jain, Farhad Ravandi, Uday R. Popat, Marina Konopleva, Patrick K. Reville, Michael Andreeff, Hagop M. Kantarjian, Maro Ohanian, Guillermo Montalban-Bravo, Gautam Borthakur, Kelly Marek, Nicholas J. Short, Koji Sasaki, Alessandra Ferrajoli, Ghayas C. Issa, Tapan M. Kadia, Mark Brandt, Courtney D. DiNardo
Publikováno v:
Blood. 138:367-367
Background The combination of venetoclax and 5-azacytidine (5-AZA) for older and unfit patients with newly diagnosed AML has led to significant improvements in remission rates and survival compared to 5-AZA alone. We previously reported encouraging r